How does MPEP 2434 address variants of claimed nucleotide sequences?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice.
MPEP 2434 provides guidance on how to handle variants of claimed nucleotide sequences in patent applications. The section states:
Direct quote: “If the application contains a claim directed to a nucleotide sequence that is set forth by SEQ ID NO, and the claim recites a specific limitation of the sequence or variants thereof, the claim should be examined.”
This guidance implies that:
- Variants of a claimed sequence are considered part of the examination process
- Examiners should review claims that include specific limitations on sequence variants
- The examination should ensure that the specification provides adequate support for the claimed variants
When addressing variants, applicants should clearly define the scope of the variants in their claims and provide sufficient written description to support the claimed variants. Examiners will assess whether the disclosed variants meet the patentability requirements, including novelty, non-obviousness, and enablement.